KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) EBITDA Margin (2016 - 2025)

Emergent BioSolutions (EBS) has 15 years of EBITDA Margin data on record, last reported at 18.76% in Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1388.0% year-over-year to 18.76%; the TTM value through Dec 2025 reached 13.47%, up 2643.0%, while the annual FY2025 figure was 13.47%, 2389.0% up from the prior year.
  • EBITDA Margin reached 18.76% in Q4 2025 per EBS's latest filing, down from 33.1% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 36.32% in Q4 2021 and bottomed at 407.0% in Q2 2024.
  • Average EBITDA Margin over 5 years is 31.95%, with a median of 10.25% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: crashed -32032bps in 2024, then soared 40814bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 36.32% in 2021, then plummeted by -152bps to 18.9% in 2022, then increased by 16bps to 15.84% in 2023, then surged by 69bps to 4.88% in 2024, then tumbled by -285bps to 18.76% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 18.76% in Q4 2025, 33.1% in Q3 2025, and 1.14% in Q2 2025.